CHECKMATE-577

NCT02743494 📎

Regimen

Experimental
nivolumab (adjuvant)
Control
placebo

Population

Resected (R0) stage II/III esophageal or GEJ cancer with residual pathological disease after neoadjuvant chemoradiotherapy

Key finding

mDFS 22.4 vs 11.0 mo (HR 0.69, 96.4% CI 0.56-0.86, P<0.001). Approved globally as SoC adjuvant for non-pCR EC/GEJ post-neoadj CRT.

Source: PMID 33789008

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.119)